ONCOVITA and UNITHER Pharmaceuticals partner to develop a new prophylactic vaccine based on Measovir® and Euroject® technologies Paris, March 13, 2025 – ONCOVITA, a biotechnology company specializing in innovative vaccine development and a spin-off from the Institut Pasteur, and UNITHER Pharmaceuticals, a global leader in sterile unit-dose manufacturing, announce a strategic partnership to develop and produce a new combined prophylactic vaccine for the prevention of infectious diseases in children. This collaboration combines Measovir®, ONCOVITA’s proprietary platform designed to develop highly immunogenic vaccines, with Euroject®, UNITHER Pharmaceuticals’ Blow-Fill-Seal (BFS)-based single-dose injection system for the direct administration of vaccines and biologics. The objective is to provide an effective, economical, and accessible solution, suitable for large-scale production. “We design innovative vaccines using a disruptive technology, with the ambition of proving the concept in humans and then bringing these advances to the bedside in partnership with pharma companies. This partnership with Unither allows us to explore the integration of Measovir® and Euroject® for simplified administration of a vaccine based on a live attenuated measles strain. Our objective: an effective, safe and easy-to-deploy solution to better protect patients worldwide”, says Dr Jean-François Le Bigot, President of ONCOVITA. “We firmly believe that combining the Measovir® technology with the Euroject® device represents a major breakthrough in making vaccination simpler, safer, and more effective at large scale. By facilitating vaccine administration and improving accessibility, we contribute to enhancing and simplifying patients’ lives while addressing today’s and tomorrow’s global public health challenges,” indicates Eric Goupil, President of Unither Pharmaceuticals. About Measovir® Measovir® is based on an attenuated measles virus strain that has been used in vaccination for over 50 years with an excellent safety profile. This plug-and-play platform allows the payloading of specific genes from other pathogens, transforming the measles vaccine virus into a vector capable of eliciting a robust and durable immune response against various infectious diseases. It is distinguished by its strong activation of both innate and adaptive immune defenses, ensuring a high level of efficacy and safety. About Euroject® Euroject® is an innovative device based on Blow-Fill-Seal (BFS) technology for the single-dose injection of therapeutic products. This pre-filled single-dose device enables vaccines to be administered simply, safely and economically, thereby reducing costs and facilitating the logistics of large-scale vaccination. A dedicated building at Unither’s Amiens site, equipped with five filling lines, will enable the company to produce more than a billion doses a year. About Oncovita: Oncovita, a spin-off from the Institut Pasteur, is a biotechnology company focused on the design and early development of innovative therapeutic and prophylactic vaccines targeting various cancers and infectious diseases. Its vaccine candidates are developed using its proprietary Measovir® technology platform, which enables genetic modification of the measles vaccine virus. Candidates developed using this plug-and-play platform include MVdeltaC, an oncolytic virus with strong immunogenic apoptotic activity for solid tumors, as well as several prophylactic combined vaccines against infectious diseases. Oncovita’s mission is to advance its vaccine candidates from the preclinical stage to clinical proof of concept. The company was a prizewinner in the ‘Innovations in Biotherapies and Bioproduction’ program under the French Health Innovation Plan 2030. https://www.oncovita.fr About Unither Pharmaceuticals Unither Pharmaceuticals is a pharmaceutical subcontractor specializing in the development and manufacturing of unit-dose and multidose liquid formulations (including eye drops, saline solutions, asthma medications in BFS unit doses, and oral liquid stick-packs) for originator pharmaceutical companies and generic manufacturers. With 2,300 employees and eight manufacturing plants across France, the United States, Brazil and China, as well as an R&D center in France, Unither Pharmaceuticals reported sales of EUR 522 million in 2024. www.unither-pharma.com Press contacts: Unither Pharmaceuticals: Elisabeth ALIDOU, contact@unither-pharma.com Oncovita: contact@oncovita.fr
